Insiders · ZNTL

Melissa B, Epperly

Chief Financial Officer at Zentalis Pharmaceuticals, Inc. (ZNTL)

Melissa B, Epperly has filed 51 insider reports with the SEC since February 2021, as director at Roivant Sciences Ltd. (ROIV), director at Nautilus Biotechnology, Inc. (NAUT) and director at Kinnate Biopharma Inc. (KNTE) and at 1 more company. In the last 12 months Melissa B, Epperly sold $2.01M of stock on the open market. The latest filing, on September 18, 2026, reports grant or award at Roivant Sciences Ltd. (ROIV).

Filings
51
Companies
4
Bought on market
$500K
Sold on market
$4.68M

Companies where Melissa B, Epperly is an insider

CompanyRoleShares heldBoughtSoldAvg buyPrice nowLast filing
Roivant Sciences Ltd. logo
ROIV
Roivant Sciences Ltd.
Directorsince June 202214,954$2.01M$38.655Sep 18, 2026
Nautilus Biotechnology, Inc. logo
NAUT
Nautilus Biotechnology, Inc.
Directorsince June 2021$2.12Jun 22, 2026
Kinnate Biopharma Inc. logo
KNTE
Kinnate Biopharma Inc.
DirectorApr 5, 2024
Zentalis Pharmaceuticals, Inc. logo
ZNTL
Zentalis Pharmaceuticals, Inc.
Chief Financial Officer451,449$500K$2.67M$52.00$1.36-97%Feb 13, 2024

Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record. Price now: the latest daily close, against the average buy price.

Every filing

Compare Melissa B, Epperly with

Other insiders at the same companies

Questions about Melissa B, Epperly

What is Melissa B, Epperly's role at Zentalis Pharmaceuticals, Inc.?
Melissa B, Epperly reports to the SEC as chief Financial Officer at Zentalis Pharmaceuticals, Inc. (ZNTL), according to the latest filing on February 13, 2024. Melissa B, Epperly has also filed as director at Roivant Sciences Ltd. (ROIV), director at Nautilus Biotechnology, Inc. (NAUT) and director at Kinnate Biopharma Inc. (KNTE).
How many shares does Melissa B, Epperly own?
After the latest filing that states it, Melissa B, Epperly directly owned 14,954 shares of Roivant Sciences Ltd. (ROIV) and 451,449 shares of Zentalis Pharmaceuticals, Inc. (ZNTL). Shares held through trusts, funds or family members are reported separately and are not counted here.
Has Melissa B, Epperly bought or sold stock recently?
The most recent open-market purchase was on August 19, 2021: bought 9,611 shares of Zentalis Pharmaceuticals, Inc. (ZNTL) for $500K at an average of $52.00. The most recent open-market sale was on September 15, 2026: sold 4,938 shares of Roivant Sciences Ltd. (ROIV) for $196K at an average of $39.74.
How do I get alerts when Melissa B, Epperly files?
Follow Melissa B, Epperly on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale. Melissa B, Epperly filed 3 times in the last 90 days.

From SEC Forms 3, 4, 5 and 144 filed by Melissa B, Epperly (SEC CIK 0001807359). Totals count each trade once, skipping amendments whose original is on file, from Feb 3, 2021 on. View on SEC EDGAR · Get this as JSON